Table 1 Baseline demographic and clinical characteristics of 1786 patients treated with amiodarone
From: A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity
Mean ± SD or number (%) | p value | ||
|---|---|---|---|
With amiodarone pulmonary toxicity | Without amiodarone pulmonary toxicity | ||
Gender, male | 22 (64.7%) | 1085 (61.9%) | 0.741 |
Age, years | 78.6 ± 11.7 | 73.6 ± 14.1 | 0.110 |
Current or ex-smoker | 15 (44.1%) | 500 (28.5%) | 0.047 |
Cardiac diagnosis | 0.231 | ||
Arrhythmia alone | 7 (20.6%) | 462 (26.4%) | 0.308 |
Ischemic heart disease | 17 (50.0%) | 710 (40.5%) | 0.420 |
Chronic rheumatic heart disease | 1 (2.9%) | 249 (14.2%) | 0.183 |
Cardiomyopathy | 6 (17.6%) | 247 (14.1%) | 0.397 |
Miscellaneous | 3 (8.8%) | 84 (4.8%) | 0.207 |
Underlying arrhythmia | |||
Supraventricular arrhythmia | 17 (50.0%) | 1259 (71.9%) | 0.005 |
Ventricular arrhythmia | 17 (50.0%) | 491 (28.1%) | 0.009 |
Underlying lung disease | 0.071 | ||
Asthma | 1 (2.9%) | 40 (2.3%) | 0.683 |
Bronchiectasis | 1 (2.9%) | 23 (1.3%) | 0.332 |
Chronic obstructive pulmonary disease | 6 (17.6%) | 106 (6.1%) | 0.005 |
Miscellaneous | 0 (0%) | 3 (0.2%) | 0.824 |
eGFR, ml/min/1.73m2 | 60.8 ± 24.7 | 64.4 ± 32.1 | 0.303 |
Duration of amiodarone, months | 70.5 ± 43.1 | 46.1 ± 54.3 | 0.019 |
Daily amiodarone dose, mg | 170.6 ± 52.4 | 165.3 ± 70.2 | 0.252 |
Cumulative dose, gram | 356 ± 246 | 217 ± 306 | 0.421 |
Amiodarone related thyroid dysfunction | 0.535 | ||
Thyrotoxicosis | 2 (5.9%) | 100 (5.7%) | 0.326 |
Hypothyroidism | 5 (14.7%) | 160 (9.1%) | 0.910 |